

Figure S1. Pilot screening of different cancer cell lines for TGZ sensitivity. Cells were treated with 0, 20 or 40 μ M of TGZ for 48 h and underwent SRB assays to assess surviving fractions. *P<0.05; †P<0.005; ‡P<0.001 compared to untreated controls. TGZ, troglitazone; SRB, sulforhodamine-B.

